Price
$3.17
Decreased by -3.35%
Dollar volume (20D)
3.03 M
ADR%
4.10
Earnings report date
Jul 31, 2025
Shares float
136.36 M
Shares short
13.77 M [10.10%]
Shares outstanding
191.53 M
Market cap
628.21 M
Beta
1.24
Price/earnings
N/A
20D range
3.04 3.65
50D range
2.94 3.73
200D range
2.71 4.35

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.

Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.

The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology.

The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.

Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Apr 30, 25 -0.18
Decreased by -81.60%
-0.15
Decreased by -18.08%
Feb 26, 25 -0.10
Increased by +16.75%
-0.12
Increased by +14.47%
Nov 6, 24 -0.09
Increased by +25.00%
-0.09
Aug 1, 24 -0.11
Decreased by -10.00%
-0.10
Decreased by -10.00%
May 2, 24 -0.10
Increased by 0.00%
-0.11
Increased by +9.09%
Feb 29, 24 -0.12
Increased by +14.29%
-0.12
Nov 7, 23 -0.12
Increased by 0.00%
-0.11
Decreased by -9.09%
Aug 3, 23 -0.10
Increased by 0.00%
-0.11
Increased by +9.09%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 1.76 M
Increased by +15.14%
-24.53 M
Decreased by -37.21%
Decreased by -1.39 K%
Decreased by -19.16%
Dec 31, 24 1.57 M
Decreased by -26.62%
-12.53 M
Increased by +35.11%
Decreased by -796.19%
Increased by +11.57%
Sep 30, 24 1.34 M
Decreased by -71.25%
-19.72 M
Increased by +1.92%
Decreased by -1.47 K%
Decreased by -241.18%
Jun 30, 24 1.73 M
Decreased by -62.89%
-19.80 M
Decreased by -15.81%
Decreased by -1.15 K%
Decreased by -212.06%
Mar 31, 24 1.53 M
Decreased by -77.09%
-17.88 M
Decreased by -15.60%
Decreased by -1.17 K%
Decreased by -404.57%
Dec 31, 23 2.15 M
Decreased by -65.65%
-19.31 M
Increased by +15.71%
Decreased by -900.33%
Decreased by -145.41%
Sep 30, 23 4.66 M
Decreased by -21.74%
-20.10 M
Decreased by -16.05%
Decreased by -431.60%
Decreased by -48.29%
Jun 30, 23 4.65 M
Decreased by -67.34%
-17.09 M
Decreased by -19.75%
Decreased by -367.53%
Decreased by -266.66%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY